Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient | Zendy

Uta Köpf | Zendy; H. U. Klehr | Zendy; Anna-Maria Eis-Huebinger | Zendy; Souhaib Aldabbagh | Zendy; Christian P. Strassburg | Zendy; Dominik Boes | Zendy; Philipp Lutz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient

Author(s) -

Uta Köpf,

H. U. Klehr,

Anna-Maria Eis-Huebinger,

Souhaib Aldabbagh,

Christian P. Strassburg,

Dominik Boes,

Philipp Lutz

Publication year - 2020

Publication title -

european journal of case reports in internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.125

H-Index - 1

ISSN - 2284-2594

DOI - 10.12890/2020_001622

Subject(s) - ganciclovir , medicine , cidofovir , cytomegalovirus , tacrolimus , cytomegalovirus infection , kidney transplantation , disease , foscarnet , drug resistance , immunology , transplantation , human cytomegalovirus , virus , herpesviridae , viral disease , biology , microbiology and biotechnology

Infection with cytomegalovirus (CMV) with resistance to ganciclovir (GCV) is a therapeutic challenge in kidney transplant patients, because standard treatment options are nephrotoxic. We report the case of a kidney transplant recipient with GCV-resistant CMV disease, in whom letermovir, a novel inhibitor of CMV packaging, was administered off-label and prevented a relapse of disease once the CMV load was decreased by cidofovir. Furthermore, we observed significant drug interactions between letermovir and tacrolimus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research